Department of Radiology, University of Cambridge School of Clinical Medicine.
Contact: Email: Jamie MacKay
I am a radiologist interested in a variety of musculoskeletal conditions, particularly osteoarthritis. My research to date has predominantly focussed on the assessment of subchondral bone using magnetic resonance (MR) imaging. I read medicine at Magdalene College, Cambridge, graduating in 2010. Following this I joined the Academic Foundation Programme in Norwich, obtaining the MRCP in 2012. I subsequently entered Radiology specialist training in Norwich, being awarded the FRCR in 2015, prior to starting my PhD with the University of Cambridge Department of Radiology in April 2016.
|Qualification||Field of Study||Institution||Year Awarded|
|FRCR||Radiology||Royal College of Radiologists||2015|
|MRCP||Medicine||Royal College of Physicians||2012|
|MB BChir||Medicine||University of Cambridge||2010|
|MA (Cantab.)||Medical Sciences||University of Cambridge||2007|
Osteoarthritis; magnetic resonance imaging; subchondral bone; cartilage; synovium; muscle; osteochondral junction; trochlear dysplasia; axial spondyloarthritis
Osteoarthritis; sarcopenia; trochlear dysplasia; axial spondyloarthritis
Texture analysis; cartilage mapping; trabecular analysis; magnetic resonance imaging
Dr Josh Kaggie MR Physics
Dr Martin Graves MR Physics
Prof Andrew McCaskie Orthopaedics
Dr Rob Janiczek GSK
Dr Jonathan Larkin GSK
Dr Danielle Gerlag GSK
Prof Andoni Toms Radiology, Norfolk & Norwich University Hospital
MacKay JW, Low SBL, Houston G, Toms AP ‘Ultrashort TE evaluation of the osteochondral junction in OA’. RSNA 2015
MacKay JW, Murray PJ, Low SBL, Kasmai B, Johnson G, Donell ST, Toms AP ‘Quantitative analysis of tibial subchondral bone: texture analysis outperforms conventional trabecular morphometry’. ISMRM/IWOAI OA Imaging Workshop 2015
MacKay JW, Murray PJ, Kasmai B, Johnson G, Donell ST, Toms AP ‘Quantitative MRI evaluation of subchondral sclerosis at the tibial plateau’. European Congress of Radiology 2015
MacKay JW, Godley KC, Toms AP, Donell ST ‘Trochlear boss height: a comparison of plain radiographs and MRI’ British Association for Surgery of the Knee 2014
MacKay JW, Aboelmagd S, Gaffney JK ‘Correlation between clinical and MRI disease activity scores in axial spondyloarthritis’ UK Radiological Congress 2013
MacKay JW, Low SBL, Houston, GC Toms AP ‘Ultrashort TE evaluation of the osteochondral junction in vivo: a feasibility study’. British Journal of Radiology 2016 doi: 10.1259/bjr.20150493
MacKay JW, Murray PJ, Kasmai B, Johnson G, Donell ST, Toms AP ‘MRI texture analysis of subchondral bone at the tibial plateau’. European Radiology 2015 doi: 10.1007/s00330-015-4142-0
MacKay JW, Murray PJ, Low SBL, Kasmai B, Johnson G, Donell ST, Toms AP ‘Quantitative analysis of tibial subchondral bone: texture analysis outperforms conventional trabecular microarchitecture analysis’. Journal of Magnetic Resonance Imaging 2015 doi: 10.1002/jmri.25088
MacKay JW, Godley KC, Toms AP ‘MRI signal based quantification of subchondral bone at the tibial plateau: a population study’. Skeletal Radiology 2014: 43: 1567-75.
MacKay JW, Godley KC, Toms AP, Donell SD ‘Trochlear boss height measurement: a comparison of plain radiographs and MRI’. The Knee 2014: 21(6):1052-7.
Addenbrooke’s Charitable Trust Clinical Research Training Fellowship (2016-7)
University of Cambridge Experimental Medicine Initiative Training Scheme (2017-9)
Osteoarthritis is a common, debilitating condition affecting one third of people aged 40 and over in the UK. Testing new treatments designed to prevent disease progression or reverse the disease process is difficult, as the disease develops slowly and can behave in a number of different ways. It is therefore very difficult to design adequately powered studies to test new treatments using existing outcome measures. Novel magnetic resonance (MR) imaging techniques have the potential to solve this problem by providing sensitive, localised markers of biochemical and structural damage to the joint. These may enable us to determine whether or not treatments are working at a very early stage. This has the potential to speed up the development of new treatments which are shown to be effective, and reduce the amount of time and money wasted on testing treatments which show no benefit.